Report Overview

The South Korea inflammatory bowel disease (IBD) market size stood at around USD xx billion in 2019 and is projected to reach xx billion by 2028, exhibiting a CAGR of around xx % during the forecast period.

Inflammatory bowel disease is a type of autoimmune disease. Inflammation occurs repeatedly due to necrosis of the mucous membrane of the digestive tract. Symptoms include weight loss, abdominal pain, and digestive tract spasms. The pathogenesis of IBD is not yet clear. Still, it is thought that the onset of the immune response to intestinal microorganisms persists in individuals with a genetic predisposition, and environmental factors, such as food and smoking, are involved in the pathogenesis.

In recent years, many patients have found that symptom improvement alone cannot prevent progressive bowel damage and intestinal complications. Recently, there is a tendency to actively treat the disease from the onset to improve mucosal healing as well as improve symptoms.

Market Drivers

The number of people with IBD in Korea had increased steadily to about 66,000 registered patients as of 2018. The awareness for disease and treatment are both rising in the population, these are the primary drivers for this market. Furthermore, rise in pollution levels, eating unhealthy food, eating at odd timings, alcohol and tobacco consumption are other factors that impact the growth of market positively. Moreover, increasing number of drugs in clinical trial and growing popularity of prebiotic and probiotic foods is likely to spur market growth.

However, high capital investments required for drug discovery, unsatisfactory effectiveness of treatment, and stringent drug regulatory policies are restraining the growth of the inflammatory bowel disease treatment market.